Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals’ cystic fibrosis drug is not “discrimination.”
Kreis, whose 18-year-old daughter has cystic fibrosis, was referring to how some critics responded to ICER’s suggestion that the drug, Trikafta, was too expensive at $312,000.
“The idea that it is discrimination to hold Vertex accountable for the obscene price of Trikafta has to do with a key metric employed by ICER in its analysis,” he writes in a piece published on the Morning Consult. “At issue is the Quality-Adjusted Life Year.”
To read the full article, click here.